Background: Erythema nodosum leprosum may appear before, during or after treatment of leprosy and is one of the main factors for nerve damage in patients. When it occurs or continues to occur after treatment, it may indicate disease recurrence and a new treatment may be instituted again. oBjective: To evaluate the retreatment of patients with multibacillary leprosy who underwent standard treatment with multidrug therapy, but developed or continued to present reactions of erythema nodosum leprosum and/or neuritis 3-5 years after its end. Method: For this objective, a new treatment was performed in 29 patients with multibacillary leprosy who maintained episodes of erythema nodosum and/or neuritis 3-5 years after conventional treatment. results: In general, we observed that 27 (93.10%) had no more new episodes after a follow up period of eight months to five years. In five of these patients the reason for the retreatment was the occurrence of difficult-to-control neuritis, and that has ceased to occur in all of them. study liMitations: Small number of patients.. conclusion: in the cases observed, retreatment was an effective measure to prevent the occurrence of erythema nodosum leprosum and/or persistent neuritis.
INTRODUCTION
Leprosy started to manifest in Brazil since the 16th Century, when it was brought by the first colonizers and slaves. 1 Since then, this disease is considered a public health problem in the country. 2 It is an infectious, contagious disease caused by Mycobacterium leprae that presents in approximately 4.68 to every 10,000 inhabitants. 2 Its first symptoms and signs are dermato-neurological, and early diagnosis and treatment are important to prevent severe consequences to the patients and their family members due to the lesions that can physically incapacitate them.
Treatment employed for multibacillary leprosy is the multidrug therapy (MDT), performed by the assocation of rifampicin, dapsone and clofazimine. MDT leads to bacillary death enabling cure of the disease, preventing its transmission, thus breaking the epidemiologic chain. 3 However, there might be cases of recurrence, even if the individual is considered cured after standard treatment. According to WHO, the definition of recurrence is reappearance of the disease at any time after a complete course of MDT. 4 The criteria for the suspicion and diagnosis of recurrence after discharge due to cure in the multibacillary form are the appearance of new skin lesions or worsening of the previous ones, new neurological disturbances with no response to the recommended course of corticosteroids, clinical picture suggestive of the disease, late reaction episodes (five years after discharge) and increase of 2+ in the bacteriological index (BI) when compared to the one after discharge. [4] [5] [6] Currently, recurrence rates between 3% and 17% are seen, Bacilloscopic tests were performed at Instituto Lauro de Souza Lima, in Bauru, São Paulo.
The patients who fulfilled the criteria for retreatment and that finished it were observed regarding the above-mentioned aspects during the consultations at the outpatient clinic.
In the case of persistent reaction episodes after treatment, these were classified in mild, moderate and severe. 14 In graph 2 the results achieved with retreatment can be seen.
Of the 29 patients who finished the retreatment, 27 (93.10%) had complete resolution of ENL and/or neuritis, with a follow up between eight months to five years, while two (6.89%) did not achieve resolution, and this result was considered very significant (p < 0.001). These two (6.89%) patients who did not improve are taking thalidomide (100mg/day), and are under control.
In graph 3 the results according to the reasons for retreatment and the resolution of the clinical picture are displayed.
Regarding the reason for retreatment, we observed that in 14 (48.27%) patients it was because of recurrent ENL, in 10 (34.38%), for having so many ENL episodes with neuritis and in five (17.24%), due to difficult-to-control neuritis (p < 0.05). Therefore, in total, there were 24 patients with ENL. Of the patients that retreated because of recurrent episodes of ENL, only two (8.33%) did not get any response. All the patients (100%) who reported difficult-to-control neuritis had a response with resolution of the clinical picture, including those who had that in association to ENL (Graph 3).
In graph 4 the results of the bacilloscopy are shown, and in graph 5, the morphological index (MI).
Bacilloscopy from all patients were collected before retreat- Of the 17 bacilloscopic tests performed, 11 were positive and, among these, six (54.5%) had a positive morphological index and five (45.5%) had a negative MI (p > 0.05).
DISCUSSION
In this study we tried to evaluate patients with multibacillary leprosy who developed or maintained reaction episodes of ENL and/or neuritis 3-5 years after finishing treatment. Although there is considerable difficulty in considering these cases as recurrences, reinfection or resistance, we considered them as possible disease recurrences likely due to insufficient treatment, that is, the 12 doses of the medication might not have been enough for the cure. Therefore, they underwent a new treatment or retreatment, as suggested by the Ministry of Health. 2, 16 These patients had episodes of ENL or neuritis every time thalidomide or corticosteroids were discontinued.
They had no clinical signs of disease or activity.
Lastória et al. 6 patients with repeat difficult-to-treat episodes could be part of a group considered as recurrence and would deserve another treatment.
Considering the results obtained above, we could observe that 27 (93.10%) patients stopped developing ENL-type reaction episodes or neuritis, while only two (6.89%) continued to present them but were controlled with thalidomide, and when this was discontinued, the episodes were considered to be mild when they reappeared. However, even though the assessment for drug resistance was not performed in these patients, both had bacillary growth and were considered resistant to rifampicin, which was posteriorly replaced by ofloxacin. These patients have not developed reaction Thalidomide was discontinued in these patients as the ENL episodes were controlled, and it is important to highlight that they had a follow-up of 8 months to 5 years, and showed no signs of ENL and/or neuritis, and there was no more need for treatment for the reactions or for the neuritis.
Therefore, the authors suggest that after the first episode of ENL, thalidomide 100mg/day be maintained for about six months, with the possibility of disappearance.
14 On the other hand, we also suggest that whenever possible, a BI with a MI be performed, what could indicate ongoing treatment in the cases where the latter is positive or in the cases where there is an increase in the BI. 6, 16 If these procedures are not feasible and the reaction episodes continue, a new treatment can be instituted. And, in these cases, it would be interesting to collect samples for the assessment of the ability of bacillary multiplication and drug resistance.
Our sample can be considered small, but it has importance, and other studies are needed. Patients in this study will continue follow-up. Therefore, in total, even not finishing the retreatment, three patients did not have reaction episodes anymore.
CONCLUSION
Although there is a possibility of a retreatment according to the recommendation of the Ministry of Health, there are no reports of studies in the literature that confirm its benefit. However, some colleagues use this strategy but do not show any results in the literature. We also considered that the Informative Note n.º 51, 2015, of the Ministry of Health, 16 supports this study, since it started and ended a long time before this publication.
Something else to be considered is that there is a rate of about 20% of noncompliance to leprosy treatment. 16 In this study, despite the patients having been submitted to a new MDT (12 doses of treatment), all were compliant.
Thus, be it for insufficient treatment or any other reason such as drug resistance, these patients can be considered as possible cases of disease recurrence and can maintain the epidemiological chain of transmission. Regarding resistance, we can consider that it was not the case in these patients, since they responded to the new treatment with no occurrence of reaction episodes.
With these results, the authors suggest that the continuity of appearance of reactions or neuritis after a specified time from the recommended treatment could be considered as possible cases of re- 
